Life Science Connect acquires PharmaSource, CDMO Live
PENNSYLVANIA, UNITED STATES — Life Science Connect has acquired PharmaSource and CDMO Live from Life Science Networks, creating what the PE-backed buyer calls the world’s leading biopharma outsourcing platform — a deal that brings together four media and events brands and installs Life Science Connect’s AI-enabled technology and institutional capital behind the combined portfolio, according to a press release.
PE backing signals biopharma outsourcing market maturity
The combined portfolio serves approximately 50,000 biopharma outsourcing professionals through events across Europe and the Americas and PharmaSource’s online buyer community.
Co-founders Luke Bilton and Chris Kilbee join Life Science Connect as Senior Vice Presidents, preserving founding team continuity through CDMO Live Americas in Boston in October 2026 and CDMO Live Europe in Rotterdam in May 2027.
Life Science Connect will supply AI-enabled technology and institutional capital, backing from Latticework Capital Management and Edgehill Management, to accelerate the combined portfolio’s commercial development.
“To build and grow our events division, our approach is to start with great people, entrepreneurs with a vision of how to provide specific audiences with actionable content and connections,” said Jon Howland, CEO of Life Science Connect.
Bootstrapped startup joins institutional platform for scale
Life Science Networks bootstrapped from launch to profitability — earning the AEO Excellence Award for Best Event Launch in June 2026 — without a single round of external financing. The acquisition provides the founders’ brands with the technology investment and distribution reach that independent bootstrapping cannot deliver at pace.
The transaction follows a recurring pattern: PE-backed platforms consolidating the events and media infrastructure of an outsourcing sub-sector once it reaches sufficient commercial scale.
“Winning the AEO Excellence Award for Best Event Launch feels like a meaningful validation of that bet. The timing now feels right to accelerate — the market is moving fast, and joining forces with Life Science Connect means we can scale at the pace the opportunity demands,” said Luke Bilton, Co-founder, Life Science Networks.
The deal marks an inflection point for biopharma outsourcing: SNS Insider projects the global CDMO market will reach $281 billion by 2032, with offshore CDMO operations across India, China, and Eastern Europe already accounting for a material share of that growth.
When institutional capital moves to consolidate the commercial and technology infrastructure of an outsourcing sub-sector, it signals the underlying market has reached the scale and predictability that platform investment demands.
For the broader outsourcing industry, Life Science Connect’s move sets a template — the information infrastructure moment that typically precedes the next wave of commercial consolidation.
